Literature DB >> 11779418

Lethal toxicity, severe endothelial injury, and a threshold effect with high doses of an adenoviral vector in baboons.

Núria Morral1, Wanda K O'Neal, Karen Rice, M Michelle Leland, Pedro A Piedra, Estuardo Aguilar-Córdova, K Dee Carey, Arthur L Beaudet, Claire Langston.   

Abstract

The effects of intravenous administration of a first-generation adenoviral vector expressing beta-galactosidase were compared in two baboons receiving a high dose or lower dose of vector, 1.2 x 10(13) or 1.2 x 10(12) particles/kg, respectively. The high-dose baboon developed acute symptoms, decreased platelet counts, and increased liver enzymes, and became moribund at 48 hr after injection, while the lower-dose baboon developed no symptoms. Expression of the beta-galactosidase transgene was prominent in liver, spleen, and endothelium of the arterial vasculature in the high-dose baboon, but was much more limited and spared the endothelium in the lower-dose baboon. Injury to the vascular endothelium was the most prominent abnormality in the high-dose baboon. Extensive histological studies provide a detailed picture of the pathology associated with a lethal dose of first-generation adenoviral vector in a primate.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11779418     DOI: 10.1089/10430340152712692

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  60 in total

1.  Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy.

Authors:  Makoto Sato; Mai Johnson; Liqun Zhang; Baohui Zhang; Kim Le; Sanjiv S Gambhir; Michael Carey; Lily Wu
Journal:  Mol Ther       Date:  2003-11       Impact factor: 11.454

Review 2.  Gene therapy: light is finally in the tunnel.

Authors:  Huibi Cao; Robert S Molday; Jim Hu
Journal:  Protein Cell       Date:  2012-01-10       Impact factor: 14.870

3.  Enhanced adenovirus transduction of hMSCs using 3D hydrogel cell carriers.

Authors:  Alexander J Neumann; Josh Schroeder; Mauro Alini; Charles W Archer; Martin J Stoddart
Journal:  Mol Biotechnol       Date:  2013-02       Impact factor: 2.695

Review 4.  Current strategies and future directions for eluding adenoviral vector immunity.

Authors:  Dinesh S Bangari; Suresh K Mittal
Journal:  Curr Gene Ther       Date:  2006-04       Impact factor: 4.391

5.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

6.  Adenovirus-platelet interaction in blood causes virus sequestration to the reticuloendothelial system of the liver.

Authors:  Daniel Stone; Ying Liu; Dmitry Shayakhmetov; Zong-Yi Li; Shaoheng Ni; André Lieber
Journal:  J Virol       Date:  2007-02-14       Impact factor: 5.103

7.  Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons.

Authors:  Shaoheng Ni; Kathrin Bernt; Anuj Gaggar; Zong-Yi Li; Hans-Peter Kiem; André Lieber
Journal:  Hum Gene Ther       Date:  2005-06       Impact factor: 5.695

8.  Correction of hyperbilirubinemia in gunn rats using clinically relevant low doses of helper-dependent adenoviral vectors.

Authors:  David Dimmock; Nicola Brunetti-Pierri; Donna J Palmer; Arthur L Beaudet; Philip Ng
Journal:  Hum Gene Ther       Date:  2011-02-16       Impact factor: 5.695

9.  Lifelong elimination of hyperbilirubinemia in the Gunn rat with a single injection of helper-dependent adenoviral vector.

Authors:  Gabriele Toietta; Viraj P Mane; Wilma S Norona; Milton J Finegold; Philip Ng; Antony F McDonagh; Arthur L Beaudet; Brendan Lee
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-07       Impact factor: 11.205

10.  Pre-existing immunity and passive immunity to adenovirus 5 prevents toxicity caused by an oncolytic adenovirus vector in the Syrian hamster model.

Authors:  Debanjan Dhar; Jacqueline F Spencer; Karoly Toth; William S M Wold
Journal:  Mol Ther       Date:  2009-07-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.